Gilead and Merck announced they are temporarily pausing enrollment in a phase 2 study evaluating a once-weekly oral combination treatment regimen of islatravir and lenacapavir…
Please confirm you want to block this member.
You will no longer be able to:
Please note: This action will also remove this member from your connections and send a report to the site admin. Please allow a few minutes for this process to complete.